A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy of single dose administration for the prevention of influenza virus infection

Single dose of inhaled CS-8958 40 mg was effective as post-exposure prophylaxis to prevent the development of influenza through household contacts, as was the inhalation of 20 mg of CS-8958 once daily for 2 days. Adverse events in CS-8958 40 mg single-dose group did not differ significantly from those in the CS-8958 20 mg once daily for 2 days administration group and placebo-group. No abnormal behaviors were observed, and there were no other major safety issues.